Drugs / AE-941
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00022282 | Apr 2001 → Mar 2007 | plasma cell myeloma | AEterna Zentaris | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT00005995 | Oct 2000 → Mar 2007 | kidney cancer | AEterna Zentaris | Completed | No outcome recorded |
| Phase 3 | NCT00005838 | Mar 2000 → Feb 2007 | adenosquamous lung carcinoma, lung adenocarcinoma, lung large cell carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AE-941 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00005838 ↗ |
| Known as | Neovastat | “the anti-angiogenic agent Neovastat (shark cartilage extract AE 941)” PMID 17868728 ↗ Sep 20071“Patients receive oral AE-941 (Neovastat) twice daily.” NCT00022282 ↗ |
| Known as | Neovastat/AE-941 | “Neovastat/AE-941” NCT00005838 ↗ |
| Modality | Other / unclassified | “shark cartilage extract AE-941” NCT00005995 ↗ |
| Route | Oral | “Patients receive oral AE-941 (Neovastat) twice daily” NCT00005838 ↗ |